Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival

2018 ◽  
Vol 91 ◽  
pp. 47-55 ◽  
Author(s):  
C. Dubot ◽  
V. Bernard ◽  
M.P. Sablin ◽  
S. Vacher ◽  
W. Chemlali ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Prognostic Biomarkers ◽  
Genomic Profiling ◽  
Genomic Alterations ◽  
Comprehensive Genomic Profiling

scholarly journals Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma

Head & Neck ◽  
2017 ◽  
Vol 39 (12) ◽  
pp. 2433-2443
Author(s):  
Hongzheng Zhang ◽  
Sungjin Kim ◽  
Zhengjia Chen ◽  
Sreenivas Nannapaneni ◽  
Amy Y. Chen ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Prognostic Biomarkers ◽  
Immunodeficiency Virus

scholarly journals Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2299 ◽  
Author(s):  
Takahiro Wakasaki ◽  
Ryuji Yasumatsu ◽  
Muneyuki Masuda ◽  
Toranoshin Takeuchi ◽  
Tomomi Manako ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Progression Free Survival ◽  
Salvage Chemotherapy ◽  
Neck Squamous Cell Carcinoma ◽  
Prognostic Biomarkers ◽  
Free Survival ◽  
Reactive Protein

Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (<1.2 mg/dL) or low NLR (<7.0) values at the time of SCT induction, which was significantly associated with an improved OS (p = 0.0440, p = 0.0354). A multivariate analysis also showed that a lower CRP value was significantly associated with a better OS (p = 0.0078). We clarified the usefulness of the PC and S1 regimens as SCT. In addition, SCT with the PC regimen showed a better prognosis with a lower CRP or NLR at induction than a higher CRP or NLR. This is the first report on biomarkers of SCT in R/M HNSCC.

Abstract 1812: LncRNAs as prognostic biomarkers in head and neck squamous cell carcinoma (HNSCC)

2019 ◽  
Author(s):  
Ritu Chaudhary ◽  
Xuefeng Wang ◽  
Biwei Cao ◽  
Nicholas T. Gimbrone ◽  
Robbert JC Slebos ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Prognostic Biomarkers

scholarly journals 891P Landscape of NOTCH1 genomic alterations (GA) in head and neck squamous cell carcinoma (HNSCC) and T-ALL

2021 ◽  
Vol 32 ◽  
pp. S798-S799
Author(s):  
K. Ikenberg ◽  
G. Bratslavsky ◽  
J. Jacob ◽  
N.A. Danziger ◽  
A. Necchi ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Genomic Alterations
Sign in / Sign up

Export Citation Format

Share Document